Sangart Scores $50M

San Diego-based Sangart, a biopharmaceutical company focused on research, development and commercialization of oxygen transport agents, said today it has raised $50M in a Series F financing. The round was led by Leucadia National Corporation, and also included warrants that if exercised could provide an additional $50M in future funding. According to Sangart, this round brings the company's total raise to more than $120M. Sangart's products are focused on the area of alternatives to blood transfusions. More information »